this morning with more. fi, good money, how does it all work? . fi, good money, how does it all work? , ., . ., ., work? yes, good morning. we are at the laruest work? yes, good morning. we are at the largest centre work? yes, good morning. we are at the largest centre here work? yes, good morning. we are at the largest centre here in work? yes, good morning. we are at the largest centre here in the - work? yes, good morning. we are at the largest centre here in the uk. . the largest centre here in the uk. the blood comes in through those doors and is scanned and then it is brought over here in these trolleys, where it is then filtered. it is a 24 hour operation here, it has been going on through the night so let s meet marcus, the night manager. tell us what happens from here. where does the blood go? we us what happens from here. where does the blood go? us what happens from here. where does the blood go? we are filtering it the whole does the blood go? we are filtering it t
there waiting for help? it is talking about and who is it out there waiting for help? it is mostly for patients there waiting for help? it is mostly for patients who there waiting for help? it is mostly for patients who have there waiting for help? it is mostly for patients who have inherited i for patients who have inherited blood disorders, particularly people with sickle cell anaemia but also thalassaemia. these are people who need regular transfusion and if the match them, we usually match them for a very small portion of the blood groups that are present on the red cell. we have heard of abo and recess blood group but red cells carry 100 different other blood group that we need to match four. it is for those blood groups where it is for those blood groups where it is difficult to find a match. these people come from an ethnic minority thatis people come from an ethnic minority that is underrepresented in our donor population. that is where the mismatch comes from. the hope i
ten years of work with the very large team across several institutions. but it is very significant because as you mentioned, this is a technology that will benefit patients with very rare blood groups that are otherwise very difficult to transfused, because we simply cannot find blood donors that match them to treat them in hospital. 50 match them to treat them in hosital. ,., ., match them to treat them in hosital. ., ., , hospital. so some of that blood has been uiven hospital. so some of that blood has been given to hospital. so some of that blood has been given to people, hospital. so some of that blood has been given to people, this - hospital. so some of that blood has been given to people, this is - hospital. so some of that blood has been given to people, this is the i been given to people, this is the first time that has happened, so what can you tell us about that? what are we doing at the moment is a micro dosing study. we are only giving two spoonfuls of red cells that
it out there waiting for help? it is mostly for patients who have inherited blood disorders, particularly people with sickle cell anaemia but also thalassaemia. these are people who need regular transfusion and if we match them, we usually match them for a very small portion of the blood groups that are present on the red cell. we have heard of abo and reshus blood group but red cells carry 100 different other blood groups that we need to match four. that we need to match for. it is for those blood groups where it is difficult to find a match. these people come from an ethnic minority that is underrepresented in our donor population. that is where the mismatch comes from. the hope is that we can then store some cells that have the right blood groups to match to patients who are difficult to transfusion and we can support them without
it is a very significant development. these technologies that are coming out of academic research need to be translated into human studies. in reaching that point is the result of ten years of work with the very large team across several institutions. but it is very significant because as you mentioned, this is a technology that will benefit patients with very rare blood groups that are otherwise very difficult to transfused, because we simply cannot find blood donors that match them to treat them in hospital. so some of that blood has been given to people, this is the first time that has happened, so what can you tell us about that? what are we doing at the moment is a micro dosing study. we are only giving two spoonfuls of red cells that have developed in the lab and relabel them. after the infusion into healthy volunteers, we can actually track how long they survive and that will tell us whether they actually survive just as well and will be better than the standard red cells we der